专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011044309A1 PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：哌啶衍生物作为化合物受体活性调节剂的产物
公开(公告)号：WO2011044309A1
公开(公告)日：2011-04-14
申请号：PCT/US2010/051731
申请日：2010-10-07
申请人： BRISTOL-MYERS SQUIBB COMPANY , HYNES, John , CARTER, Percy H. , CORNELIUS, Lyndon A.M. , DHAR, T.G. Murali , DUNCIA, John V. , NAIR, Satheesh , SANTELLA, Joseph B. , WARRIER, Jayakumar S. , WU, Hong
发明人： HYNES, John , CARTER, Percy H. , CORNELIUS, Lyndon A.M. , DHAR, T.G. Murali , DUNCIA, John V. , NAIR, Satheesh , SANTELLA, Joseph B. , WARRIER, Jayakumar S. , WU, Hong
IPC分类号： C07D211/52
CPC分类号： C07D211/60 , C07D211/52 , C07F9/591 , C07F9/592
摘要： The present application describes prodrugs of the compound of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.
摘要翻译：本申请描述了式（I）化合物的前药或其立体异构体或其药学上可接受的盐。此外，公开了使用本发明的前药化合物治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎的方法。

2. 发明申请

WO2004024682A2 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. 审中-公开
标题翻译：作为化合物受体活性的调节剂的N-尿嘧啶 - 哌啶。
公开(公告)号：WO2004024682A2
公开(公告)日：2004-03-25
申请号：PCT/US0328468
申请日：2003-09-11
申请人： SQUIBB BRISTOL MYERS CO , DUNCIA JOHN V , GARDNER DANIEL S , SANTELLA JOSEPH B
发明人： DUNCIA JOHN V , GARDNER DANIEL S , SANTELLA JOSEPH B
IPC分类号： A61K31/445 , C07D401/04 , C07D401/12 , C07D
CPC分类号： C07D401/12
摘要： The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
摘要翻译：本申请描述了N-脲基烷基哌啶作为趋化因子受体的调节剂或其药学上可接受的盐形式，其可用于预防哮喘和其它过敏性疾病。

3. 发明申请

WO2011159852A1 PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为化合物受体活性的调节剂的哌啶化合物
公开(公告)号：WO2011159852A1
公开(公告)日：2011-12-22
申请号：PCT/US2011/040605
申请日：2011-06-16
申请人： BRISTOL-MYERS SQUIBB COMPANY , CHERNEY, Robert J. , DUNCIA, John V. , GARDNER, Daniel S. , SANTELLA, Joseph B. , WANG, Zhongyu
发明人： CHERNEY, Robert J. , DUNCIA, John V. , GARDNER, Daniel S. , SANTELLA, Joseph B. , WANG, Zhongyu
IPC分类号： C07D211/52 , A61K31/451
CPC分类号： C07D211/52 , A61K31/451
摘要： The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
摘要翻译：本申请描述了式（I）化合物或其立体异构体或其药学上可接受的盐。此外，公开了使用本发明的化合物治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫病态如类风湿性关节炎和关节病的方法。

4. 发明申请

WO2004024682A3 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. 审中-公开
公开(公告)号：WO2004024682A3
公开(公告)日：2004-03-25
申请号：PCT/US2003/028468
申请日：2003-09-11
申请人： BRISTOL-MYERS SQUIBB COMPANY , DUNCIA, John, V. , GARDNER, Daniel, S. , SANTELLA, Joseph, B.
发明人： DUNCIA, John, V. , GARDNER, Daniel, S. , SANTELLA, Joseph, B.
IPC分类号： A61K31/445
摘要： The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

5. 发明申请

WO2009015164A3 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为化合物受体活性调节剂的哌啶衍生物
公开(公告)号：WO2009015164A3
公开(公告)日：2009-04-23
申请号：PCT/US2008070801
申请日：2008-07-23
申请人： SQUIBB BRISTOL MYERS CO , GARDNER DANIEL S , DUNCIA JOHN V , HYNES JOHN , DHAR T G MURALI , CARTER PERCY H , SANTELLA JOSEPH B
发明人： GARDNER DANIEL S , DUNCIA JOHN V , HYNES JOHN , DHAR T G MURALI , CARTER PERCY H , SANTELLA JOSEPH B
IPC分类号： C07D211/52 , A61K31/45 , A61K31/451 , A61K31/4523 , A61P19/00 , A61P29/00 , A61P37/00 , C07D401/12 , C07D405/12
CPC分类号： C07D401/12 , C07D211/52 , C07D405/12
摘要： The present application describes modulators of MIP-1a of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
摘要翻译：本申请描述了式（I）的MIP-1a或其立体异构体或前药或其药学上可接受的盐的调节剂，其中m，Q，T，W，Z，R 1，R 3，R 4，R 5，R 5a和R 5b如上定义于此。此外，公开了使用式（I）的调节剂治疗和预防炎性疾病如哮喘和过敏性疾病以及类风湿性关节炎和动脉粥样硬化的自身免疫病态的方法。

6. 发明申请

WO2007092681A3 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为化合物受体活性调节剂的哌啶衍生物
公开(公告)号：WO2007092681A3
公开(公告)日：2009-03-12
申请号：PCT/US2007061012
申请日：2007-01-25
申请人： SQUIBB BRISTOL MYERS CO , CARTER PERCY H , CAVALLARO CULLEN L , DUNCIA JOHN V , GARDNER DANIEL S , HYNES JOHN , LIU RUI-QIN , SANTELLA JOSEPH B , DODD DHARMPAL S
发明人： CARTER PERCY H , CAVALLARO CULLEN L , DUNCIA JOHN V , GARDNER DANIEL S , HYNES JOHN , LIU RUI-QIN , SANTELLA JOSEPH B , DODD DHARMPAL S
IPC分类号： C07D211/18 , A61K31/45 , C07D211/38 , C07D211/52 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/04 , C07D491/10
CPC分类号： C07D211/52 , C07D211/18 , C07D211/38 , C07D211/58 , C07D211/70 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/107
摘要： The present application describes substituted piperidinyl modulators of MIP-1a or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
摘要翻译：本申请描述了MIP-1a或CCR-1的取代的哌啶基调节剂或其立体异构体或其药学上可接受的盐。此外，公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎和移植排斥的方法。

7. 发明申请

WO2005020899A3 SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为趋化因子受体活性调节剂的取代环胞嘧啶衍生物
公开(公告)号：WO2005020899A3
公开(公告)日：2005-06-30
申请号：PCT/US2004027195
申请日：2004-08-20
申请人： SQUIBB BRISTOL MYERS CO , CARTER PERCY H , CHERNEY ROBERT J , BATT DOUGLAS G , BROWN GREGORY D , DUNCIA JOHN V , GARDNER DANIEL S , YANG MICHAEL G
发明人： CARTER PERCY H , CHERNEY ROBERT J , BATT DOUGLAS G , BROWN GREGORY D , DUNCIA JOHN V , GARDNER DANIEL S , YANG MICHAEL G
IPC分类号： C07C237/22 , C07C275/42 , C07D205/04 , C07D207/34 , C07D213/38 , C07D213/64 , C07D213/65 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/40 , C07D231/56 , C07D233/54 , C07D235/30 , C07D239/28 , C07D239/42 , C07D239/94 , C07D257/04 , C07D261/20 , C07D271/06 , C07D277/28 , C07D295/205 , C07D295/215 , C07D307/66 , C07D307/68 , C07D401/04 , C07D413/12 , C07D487/04 , A61K31/421 , A61K31/422
CPC分类号： C07C237/22 , C07B2200/07 , C07C275/42 , C07C2601/14 , C07D205/04 , C07D207/34 , C07D213/38 , C07D213/64 , C07D213/65 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/40 , C07D231/56 , C07D233/56 , C07D235/30 , C07D239/28 , C07D239/42 , C07D239/94 , C07D257/04 , C07D261/20 , C07D271/06 , C07D277/28 , C07D295/205 , C07D295/215 , C07D307/66 , C07D307/68 , C07D401/04 , C07D413/12 , C07D487/04
摘要： The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
摘要翻译：本申请描述了用于预防哮喘，多发性硬化，动脉粥样硬化和类风湿性关节炎的式（I）的MCP-1或其药学上可接受的盐形式的调节剂。

8. 发明申请

WO2005048932A2 N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为化合物受体活性调节剂的N-尿嘧啶 - 氨基化合物
公开(公告)号：WO2005048932A2
公开(公告)日：2005-06-02
申请号：PCT/US2004/037830
申请日：2004-11-13
申请人： BRISTOL-MYERS SQUIBB COMPANY , KO, Soo, S. , BATT, Douglas, G. , DELUCCA, George, V. , DUNCIA, John, V. , GARDNER, Daniel, S. , SANTELLA, Joseph, B.
发明人： KO, Soo, S. , BATT, Douglas, G. , DELUCCA, George, V. , DUNCIA, John, V. , GARDNER, Daniel, S. , SANTELLA, Joseph, B.
IPC分类号： A61K
CPC分类号： A61K31/506 , A61K31/454 , A61K31/497 , A61K31/501 , C07C275/30 , C07C275/34 , C07C275/38 , C07C2601/02 , C07C2601/14 , C07D231/56 , C07D239/26 , C07D257/04 , C07D277/48 , C07D285/135 , C07D317/64 , C07D317/66 , C07D401/12 , C07D403/12
摘要： The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
摘要翻译：本申请描述了可用于预防哮喘和其它过敏性疾病的式（I）的趋化因子受体或其药学上可接受的盐形式的调节剂。

9. 发明申请

WO2009015164A2 ACYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开
标题翻译：作为化合物受体活性调节剂的交联衍生物
公开(公告)号：WO2009015164A2
公开(公告)日：2009-01-29
申请号：PCT/US2008/070801
申请日：2008-07-23
申请人： BRISTOL-MYERS SQUIBB COMPANY , GARDNER, Daniel S. , DUNCIA, John V. , HYNES, John , DHAR, T., G., Murali , CARTER, Percy H. , SANTELLA, Joseph B.
发明人： GARDNER, Daniel S. , DUNCIA, John V. , HYNES, John , DHAR, T., G., Murali , CARTER, Percy H. , SANTELLA, Joseph B.
CPC分类号： C07D401/12 , C07D211/52 , C07D405/12
摘要： The present application describes modulators of MIP-1α of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R 1, R 3 , R 4 , R 5 , R 5a and R 5b , are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
摘要翻译：本申请描述了式（I）的MIP-1a或其立体异构体或前药或其药学上可接受的盐的调节剂，其中m，Q，T，W，Z，R 1，R 3，R 4，R 5，R 5a和R 5b如上定义于此。此外，公开了使用式（I）的调节剂治疗和预防炎性疾病如哮喘和过敏性疾病以及类风湿性关节炎和动脉粥样硬化的自身免疫病态的方法。

10. 发明申请

WO2008014360A2 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS 审中-公开
标题翻译：化合物受体活性的调节剂，结晶形式和过程
公开(公告)号：WO2008014360A2
公开(公告)日：2008-01-31
申请号：PCT/US2007074377
申请日：2007-07-26
申请人： SQUIBB BRISTOL MYERS CO , CARTER PERCY H , DUNCIA JOHN V , MUDRYK BOGUSLAW M , RANDAZZO MICHAEL E , XIAO ZILI , YANG MICHAEL G , ZHAO RULIN
发明人： CARTER PERCY H , DUNCIA JOHN V , MUDRYK BOGUSLAW M , RANDAZZO MICHAEL E , XIAO ZILI , YANG MICHAEL G , ZHAO RULIN
IPC分类号： C07D403/12 , A61K31/4025 , C07D207/273
CPC分类号： C07D403/12 , C07D207/273 , C07D317/72
摘要： The present invention provides a novel antagonist or partial agonists/antagonist of MCP-I receptor activity: N-((lR,2S,5R)-5-(tert-butylamino)-2- ((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l- yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having an unexpected combination of desirable pharmacological characteristics. Crystalline forms of the present invention are also provided. Pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases is also an objective of this invention. The present disclosure also provides a process for preparing compounds of Formula (I), including N-((lR,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide: wherein R 1 , R 8 , R 9 , R 10 , and "HET" are as described herein. Compounds that are useful intermediates of the process are also provided herein.
摘要翻译：本发明提供MCP-1受体活性的新型拮抗剂或部分激动剂/拮抗剂：N - （（1R，2S，5R）-5-（叔丁基氨基）-2 - （（S）-2-氧代-3 - （6-（三氟甲基）喹唑啉-4-基氨基）吡咯烷-1-基）环己基）乙酰胺或其药学上可接受的盐，溶剂合物或前药，具有期望的药理学特征的意想不到的组合。还提供了本发明的结晶形式。含有该组合物的药物组合物以及使用其作为治疗炎性疾病，过敏性，自身免疫性，代谢性，癌症和/或心血管疾病的药剂的方法也是本发明的目的。本公开还提供制备式（I）化合物的方法，其包括N - （（1R，2S，5R）-5-（叔丁基氨基）-2 - （（S）-2-氧代-3-（（三氟甲基）喹唑啉-4-基氨基）吡咯烷-1-基）环己基）乙酰胺：其中R 1，R 8，R 9， >，R＆gt;和＆lt; HET＆gt;如本文所述。本文还提供了该方法有用中间体的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式